This upcoming trial in France is comparable to the Toca511/TocaFC trials in the US, in that it uses a viral vector to transmit a "suicide gene" to tumor cells that cause them to convert 5-fluorocytosine into the chemotherapy drug 5-fluorouracil. The virus used in this trial, TG6002, is also oncolytic, meaning that it can kill tumor cells, even without the suicide gene + prodrug component.
https://clinicaltrials.gov/ct2/show/NCT03294486
More information on the lab studies with this therapy can be found here.
No comments:
Post a Comment